Roche has agreed to acquire Dutalys and Bino Technologies in a end of year acquisition push.
|Searching for more deal information? Current Partnering offers the following options:
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
Bina Technologies deal
Roche announced the acquisition of Bina Technologies.
Bina provides a big data platform for centralized management and processing of next generation sequencing (NGS) data.
Bina's proprietary on-market Genomic Management Solution, Bina-GMS1, empowers basic, translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data.
The acquisition by Roche will enable Bina to accelerate product development and global commercialization of the Bina-GMS as an enterprise software system supporting multiple sequencing technologies while developing a solution for Roche sequencing systems.
Roche will also continue to grow Bina's unique interdisciplinary team of bioinformatics scientists, computer scientists and software engineers.
Bina will be integrated into Roche Sequencing Unit in Q1 2015 and will continue to focus on expanding its innovative genomic analysis solutions portfolio.
Dutalys specializes in the discovery and development of fully human, bi-specific antibodies based on their proprietary DutaMab technology.
The bi-specific antibodies developed with this platform are designed to provide novel, best-in-class molecules for several therapeutic areas.
This deal further highlights Roche’s leadership in the development of therapeutic antibodies.
Roche will make an upfront cash payment of USD 133.75 million to shareholders and make additional contingent payments of up to USD 355 million based on the achievement of certain predetermined milestones.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Report: Top 50 Big Pharma Partnering and M&A Deal Trends
Report: Top 50 Big Biotech Partnering and M&A Deal Trends